Two human-based studies highlighted a successful use of sirolimus, an mTOR inhibitor, in reducing adenoma burden, as well as dysplastic degeneration, in FAP patients pre- and post-colectomy with ileal pouch anastomosis, making it possible to consider mTOR inhibitors as a promising potential chemopreventive agent [77,78]. This evidence concerns the gene MTOR and adenoma.